Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The new FDA combination products programme.

Maria Donawa1

  • 1Donawa and Associates Ltd, an Aventor Partner, Via Fonte di Fauno 22, 1-00153 Rome, Italy. donawa@srd.it

Medical Device Technology
|November 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

US regulation of combination products.

Medical device technology·2010
Same author

Clinical studies in Italy.

Medical device technology·2010
Same author

Meeting US and European supplier control requirements.

Medical device technology·2009
Same author

Avoiding surprises when implementing a single quality system.

Medical device technology·2009
Same author

Addressing Eeuropean environmental legislation.

Medical device technology·2009
Same author

Addressing US and European device testing requirements.

Medical device technology·2008

The US Food and Drug Administration (FDA) created a Combination Products Programme to improve how it regulates combined drug, device, and biological products. This initiative streamlines the review process for these complex medical products.

Area of Science:

  • Regulatory Science
  • Medical Product Evaluation
  • Pharmaceutical Policy

Background:

  • Combination products, comprising drugs, devices, or biologics, present unique regulatory challenges.
  • The existing regulatory framework required enhancement to effectively oversee these multifaceted products.
  • The US Food and Drug Administration (FDA) recognized the need for a specialized approach.

Purpose of the Study:

  • To provide an overview of the FDA's regulatory landscape for combination products.
  • To introduce and explain the newly established Combination Products Programme.
  • To highlight improvements in the regulatory effectiveness for these products.

Main Methods:

  • Review of FDA's internal procedures and program establishment.

Related Experiment Videos

  • Analysis of the regulatory framework for combination products.
  • Description of the Combination Products Programme's structure and function.

    • Main Results:

    • The FDA has successfully established a dedicated Combination Products Programme.
    • A new internal procedure has been developed to enhance regulatory effectiveness.
    • The Programme aims to streamline the regulation of drug-device and drug-biologic combinations.

    Conclusions:

    • The Combination Products Programme represents a significant step in optimizing FDA regulation.
    • This initiative is expected to improve the efficiency and consistency of combination product reviews.
    • The FDA's commitment to adapting its regulatory processes is evident.